Evidence map›Paper›PMID 41199088›Full record

ArticleJournal of fluorescence2026

Detection of Four Early Tumor Biomarkers Using Micron-Sized Silica Microspheres Encoded With QDs (CQDs) for Tumor Early Screening.

Zhaobin Xu, Xinling Wang, Wenyao Li, Wenjie Yang, Na Xu, Yushi Chen, Shengnan Luo, Fang Ma, Huiping Chen, Can Wang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhaobin Xu *Henan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Xinling Wang *Henan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Wenyao LiHenan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Wenjie YangHenan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Na XuHenan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Yushi ChenHenan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Shengnan LuoHenan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Fang MaHenan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Huiping ChenHenan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Can WangDepartment of Thyroid and Breast Medicine, Henan Provincial Hospital of Traditional Chinese Medicine, Zhengzhou, China.
Liguo ZhangHenan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou, China. lgzhang@zzu.edu.cn.

Funding

Basic Research Fund of Henan Institute of Medical and Pharmaceutical Sciences 2025BP0104,2025BP0104-2Scientific and Technological Program of Henan Province 252102311195
6 · The paper itself

Abstract

Detection of tumor biomarkers is critical for early cancer diagnosis and cancer therapeutic monitoring, but traditional methods often lack sufficient sensitivity and specificity, especially at low biomarker concentrations. To address this challenge, in this study a multiplex detection platform based on core-shell quantum dot-encoded silica microspheres was developed for highly sensitive, simultaneous detection of multiple tumor biomarkers in a single assay. The core-shell silica architecture provides a high surface area for bioconjugation, while embedded quantum dots (QDs) offer strong fluorescence, making them ideal labels. Carbon quantum dots (CQDs), which have low toxicity, superior biocompatibility, and high photostability, were used as reporter molecules instead of organic dyes. This choice improved detection sensitivity and reduced the detection system's environmental toxicity relative to traditional dye-based assays. After optimizing QD-silica conjugation and immunoassay conditions, the platform achieved highly sensitive multiplex detection of four tumor biomarkers (AFP, CEA, CA125, CA19-9) commonly used in early cancer screening. Results demonstrated specific detection of all four targets within a short time frame, with excellent stability and reproducibility. By enhancing sensitivity for these biomarkers and reducing assay toxicity while improving stability, this platform shows significant potential to greatly improve early cancer screening and cancer therapeutic monitoring in clinical practice.

Indexed as

Biomarkers, TumorEarly Detection of CancerMicrospheresQuantum DotsSilicon DioxideCarbonHumansImmunoassayParticle SizeBiomarkers, TumorCarbonSilicon DioxideFluorescence encodingLiquid-phase suspension chipMulti-detectionQuantum dotsSilicon dioxide

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.